Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have concluded investment agreement with Niremia Collective, a venture capital firm specializing in Well-being Technology-focused funds (Headquarters: California, USA; Representative: Naoko Okumoto,…
The Ohio State University Wexner Medical Center and CVS Accountable Care, part of CVS Health® (NYSE: CVS), today announced the creation of an accountable care organization (ACO) to improve the quality of care for Medicare beneficiaries by Ohio State providers in central Ohio.…
Allergan Aesthetics, the industry leader in aesthetics globally, continues to bring best-in-class programming highlighting Individuality, Innovation, and Integrity at the International Master Course on Aging Science (IMCAS) World Congress 2024 in Paris from February 1-3, 2024. Events include an Allergan Medical Institute (AMI) symposium,…
Bayer today announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Ambrogio will…
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of Allē Members who have been treated in the past twelve…
Noom, the leading digital healthcare company empowering people to live better, healthier lives, is proud to announce a partnership with FitOn to add a “Muscle Defense” enhancement to its newly launched Noom GLP-1 Companion. Noom GLP-1 Companion with Muscle Defense…
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in…
Zoetis Inc. (NYSE:ZTS) has been selected as a 2024 Catalyst Award recipient for its global initiative, Awareness and Action Drives Impact, that is advancing equity for women and other underrepresented groups across the company — from the frontlines to senior leadership. Zoetis is…
Novartis today presented data from the Phase III NETTER-2 trial showing that Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled…
Global biotechnology leader CSL (ASX: CSL) today announced that Swissmedic has authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene therapy for the treatment of male adults aged >18 years with severe or moderately severe hemophilia B (congenital Factor IX deficiency).…
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation. In recognition of its Environmental, Social and Governance (ESG)…
